Breaking News

Ajinomoto Althea Gains EU GMP Certification

September 3, 2014

Will test commercial drug product for the European market

Ajinomoto Althea, Inc. has received its European GMP certificate from the Medicines and Healthcare products Regulatory Agency (MHRA) following an on-site inspection on June 19, 2014 that resulted in no critical or major observations. The certification allows the company to test commercial drug product for the European market.
 
"Althea is proud of this important regulatory milestone. We are well known for our impeccable regulatory track record in the US and now are very pleased to expand our commercial testing capabilities for European clients," said David Enloe, president and chief executive officer of Althea. "Knowing that our testing and quality processes meet both the stringent FDA and EMA quality requirements really signifies a great accomplishment by our team and supports our leadership position in the CMO market."
 
Althea provides manufacturing services including cGMP bulk manufacturing filling in vials and syringes, microbial-based biologics manufacturing, Crystalomics crystal suspension technology, process development, in-process and release testing analytics, equipment qualification, and validation.
blog comments powered by Disqus
  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?